BioCentury | Jul 29, 2020
Distillery Therapeutics

CAPN2 inhibition for concussion-associated neuropathy and behavioral changes

DISEASE CATEGORY: Neurology INDICATION: Neurology Inhibiting the calcium-dependent protease CAPN2 could treat neuropathy and behavioral changes caused by repeated concussions. In a mouse model of traumatic brain injury mediated by controlled cortical impact, excitatory neuron-specific...
BioCentury | Dec 20, 2019

CAPN3 gene therapy for limb-girdle muscular dystrophy type 2A the injected muscle and decreased RNA expression of genes previously implicated in dystrophy. TARGET/MARKER/PATHWAY: Calpain 3 (CAPN3)...
...published online Nov. 27, 2019 doi:10.1126/scitranslmed.aat6072 CONTACT: Isabelle Richard, Genethon, Evry, France email: Claire Quang Genethon Calpain 3 (CAPN3)...
BioCentury | Sep 27, 2019
Company News

Blade eyeing fibrosis combos with acquisition of PharmAkea-spinout

Blade is adding to its fibrosis pipeline with the acquisition of PharmAkea-spinout ATXco Inc. and its autotaxin inhibitor PAT-409. President and CEO Wendye Robbins said PAT-409 is complementary to Blade Therapeutics Inc.’s BLD-2660, a calpain...
BioCentury | Jul 25, 2019
Distillery Therapeutics

Inhibiting CAPN9 to treat fibrosis

DISEASE CATEGORY: Pulmonary; hepatic; cardiovascular INDICATION: Pulmonary fibrosis; liver fibrosis; cardiac fibrosis Inhibition of CAPN9 could treat fibrosis by blocking a TGFβ-induced pathway that contributes to fibrosis development. Two tool compound CAPN9 inhibitors decreased TGFβ-induced...
BioCentury | Jul 19, 2019
Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

Samumed's Alzheimer's candidate reduces tau pathology, inflammation Samumed LLC (San Diego, Calif.) reported in an Aging Cell paper that SM07883 reduced tau phosphorylation, pathological tau aggregates, neuroinflammation, weight loss and mortality in a mouse model...
BioCentury | Aug 25, 2016
Distillery Therapeutics

Therapeutics: Calpain 6 (CAPN6)

Cardiovascular disease INDICATION: Atherosclerosis Patient sample and mouse studies suggest inhibiting CAPN6 could help treat atherosclerosis. In patients, CAPN6 expression on macrophages in atheromas was associated with disease severity. In a mouse model of atherosclerosis,...
BioCentury | Apr 5, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Calpain 2 (CAPN2) In vitro and mouse studies suggest CAPN2 inhibitors could help treat breast cancer. In a mouse mammary cancer cell line,...
BioCentury | Aug 26, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Calpain 1 (CAPN1); CAPN2 In vitro and mouse studies identified analogs of CAPN1 and CAPN2 inhibitors that cross the blood brain barrier (BBB) and...
BioCentury | Aug 12, 2010
Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Gastrointestinal injury Calpain 8 (CAPN8); CAPN9 Mouse studies suggest that upregulating CAPN8 and CAPN9 in the gastrointestinal tract could help treat stress-induced gastrointestinal injury....
BioCentury | Apr 23, 2009
Targets & Mechanisms

New fronts against malaria

A key challenge in combating malaria is the rapid development of resistance that Plasmodium falciparum parasites mount against older drugs. Now, a pair of articles describes two new ways to attack the infection: inhibiting host...
Items per page:
1 - 10 of 12